It is time to reconsider leukoreduction of whole blood for use in patients with life‐threatening hemorrhage
Mark H. Yazer, Andrew Beckett, Evan M. Bloch, Andrew P. Cap, Claudia S. Cohn, Jennifer M. Gurney, Daniela Hermelin, Philip C. Spinella
Abstract
PCS consults for Hemanext, Cerus, is on the scientific advisory board for Haima and Octapharma, and is a co-founder and chief medical officer for Kalocyte. EMB reports personal fees and non-financial support from Grifols, Abbott, UpToDate, Tegus, and Health Advances outside of the submitted work. EMB is a co-investigator on a US government-funded clinical trial evaluating Mirasol Pathogen Reduction Technology. CSC is on the scientific advisory board of Fresenius-Kabi and is a consultant for Quidel OrthoClinical. MHY is on the scientific advisory board for Hemanext and has given paid lectures for Terumo BCT and Grifols. The remaining authors declare no conflict of interest.